ReviewCureus2026
Emerging Sedation Strategies in Pediatric Emergency Care: Pharmacological Advances and Clinical Applications.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Emerging sedative agents are increasingly being explored to improve the safety and effectiveness of procedural sedation in pediatric emergency care. Traditional agents such as propofol and ketamine remain widely used because of their rapid onset and clinical effectiveness; however, they may be associated with adverse effects, including hypotension, respiratory depression, and emergence reactions, which require careful monitoring during pediatric procedural sedation. In this context, newer pharmacologic approaches have been investigated to optimize safety and procedural control. Remimazolam, a benzodiazepine metabolized by tissue esterases, demonstrates rapid clearance, minimal drug accumulation, and stable hemodynamic profiles. Clinical studies suggest comparable efficacy to propofol in procedural sedation, with potential advantages including reduced respiratory depression and a lower incidence of emergence delirium. Its reversibility with flumazenil may further enhance safety in selected clinical scenarios. Dexmedetomidine, a selective α₂-adrenergic receptor agonist, provides sedation that resembles natural sleep and offers intrinsic analgesic properties with minimal respiratory depression. Although its onset of action may be slower than that of agents such as propofol, dexmedetomidine is associated with favorable respiratory stability and may be particularly useful in pediatric patients requiring cooperative or prolonged sedation. Intranasal administration represents a noninvasive alternative in situations where intravenous access has not yet been established, although its pharmacokinetic profile may result in delayed onset. These agents have been applied in a variety of pediatric procedures, including painful interventions, imaging studies, and short diagnostic procedures. Their use may be particularly valuable in children with developmental disorders or complex comorbidities, where stable hemodynamic and respiratory profiles are essential. Contemporary safety frameworks emphasize structured risk assessment, airway preparedness, weight-based dosing strategies, and continuous monitoring techniques such as capnography and pulse oximetry. Current evidence from randomized and observational studies suggests that emerging sedative strategies may provide effective procedural sedation while maintaining favorable safety profiles when appropriately integrated into multimodal sedation approaches. Nevertheless, important knowledge gaps remain, including limited pediatric data for certain agents, the need for standardized protocols, and the evaluation of long-term outcomes in younger patient populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.